Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12248256 | 0.90 | CA12 (0.59) | CYP1A2SMN1; SMN2CYP2C19CA12CA1 | |
| Hydrochloric Acid SCHEMBL27540796 | 0.89 | CA12 (0.58) | CYP1A2SMN1; SMN2CYP2C19CA12CA1 | |
| SCHEMBL12506842 | 0.84 | CA12 (0.56) | CYP1A2SMN1; SMN2CYP2C19NAAACA12 | |
| SCHEMBL11036318 | 0.84 | LMNA (0.58) | CYP1A2SMN1; SMN2CYP2C19NAAACA12 | |
| SCHEMBL11534635 | 0.83 | SMN1; SMN2 (0.55) | CYP1A2SMN1; SMN2CYP2C19NAAACA12 | |
| Ethyl Acetate SCHEMBL8398014 | 0.81 | HRH1 (0.49) | CYP1A2SMN1; SMN2CYP2C19NAAACA12 | |
| SCHEMBL27486988 | 0.81 | TDP1 (0.52) | CYP1A2SMN1; SMN2CYP2C19NAAACA12 | |
| Hydrochloric Acid SCHEMBL28739904 | 0.80 | TDP1 (0.51) | CYP1A2SMN1; SMN2CYP2C19NAAACA12 | |
| Bromide SCHEMBL28739911 | 0.80 | TDP1 (0.51) | CYP1A2SMN1; SMN2CYP2C19NAAACA12 | |
| Bromide SCHEMBL27710413 | 0.80 | TDP1 (0.51) | CYP1A2SMN1; SMN2CYP2C19NAAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829201-B2 | Electrolyte Formulations | MERCK PATENT GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-20120318360-A1 | Electrolyte Formulations | MERCK PATENT GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| CN-1328278-C | N-acylamino acid amide compounds and intermediates for preparation thereof | UBE INDUSTRIES (JP) | 2007-07-25 | — | — | CN | disclosed |
| US-6677268-B2 | A METAL COMPLEXES AS HYDROFORMYLATION CATALYST OF OLEFINICALLY UNSATURATED COMPOUNDS | INSTITUT FRANCAIS DU PETROLE (FR) | 2004-01-13 | — | — | US | disclosed |
| US-20030055299-A1 | Catalyst based on cobalt and/or rhodium employed in a two-phase medium | INSTITUT FRANCAIS DU PETROLE (FR) | 2003-03-20 | — | — | US | disclosed |
| US-6469216-B2 | CO OR RH COMPLEX COORDINATED WITH A NITROGEN-CONTAINING LIGAND; QUATERNARY AMMONIUM OR PHOSPHONIUM IONIC SOLVENT | INSTITUT FRANCAIS DU PETROLE (FR) | 2002-10-22 | — | — | US | disclosed |
| US-20010039363-A1 | Process for hydroformylation using a catalyst based on cobalt and/or rhodium employed in a two-phase medium | INSTITUT FRANCAIS DU PETROLE (FR) | 2001-11-08 | — | — | US | disclosed |
| CN-1265661-A | N-acylamino acid amide compounds and intermediates for preparation thereof | UBE INDUSTRIES (JP) | 2000-09-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | CYP1A2 2284/4885SMN1; SMN2 388/4885CYP2C19 2898/4885 |
| US-20120318360-A1 | Electrolyte Formulations | NHERF1, HCN4, DDT | CYP1A2 4508/4885SMN1; SMN2 4519/4885CYP2C19 2882/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | CYP1A2 1092/4885SMN1; SMN2 2156/4885CYP2C19 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.